<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802240</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI338A301</org_study_id>
    <nct_id>NCT03802240</nct_id>
  </id_info>
  <brief_title>Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Phase III Clinical Study Assessing the Efficacy and Safety of Sintilimab ± IBI305 Combined With Pemetrexed and Cisplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (ORIENT-31)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The anti-tumor activity of anti-PD-1 therapy and VEGF inhibitor in TKI-resistant EGFR-mutated
      Chinese non-squamous NSCLC patients will be investigated in this clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (Progression Free Survival)</measure>
    <time_frame>Time from the first dose of study drug to the first disease progression (imaging) through study completion, an average of 24 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>Time from randomization to the death of the subject due to any cause assessed up to 36 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (overall response rate)</measure>
    <time_frame>The proportion of subjects who have a complete response (CR) or a partial response (PR) assessed up to 24 months.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Sintilimab +IBI305+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sintilimab +Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo1+Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg IV Q3W</description>
    <arm_group_label>Sintilimab +IBI305+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <other_name>IBI308</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI305</intervention_name>
    <description>15mg/kg IV Q3W</description>
    <arm_group_label>Sintilimab +IBI305+Pemetrexed+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500mg/m2 IV Q3W</description>
    <arm_group_label>Placebo1+Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +IBI305+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +Placebo2+Pemetrexed+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m2 IV Q3W</description>
    <arm_group_label>Placebo1+Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +IBI305+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +Placebo2+Pemetrexed+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo1</intervention_name>
    <description>Placebo1 IV Q3W</description>
    <arm_group_label>Placebo1+Placebo2+Pemetrexed+Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo2</intervention_name>
    <description>Placebo2 IV Q3W</description>
    <arm_group_label>Placebo1+Placebo2+Pemetrexed+Cisplatin</arm_group_label>
    <arm_group_label>Sintilimab +Placebo2+Pemetrexed+Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          1. Signed written informed consent before any trial-related processes;

          2. Age ≥ 18 years and &lt;75 years male or females;

          3. Has a histologically or cytologically confirmed stage IIIB/IIIC (American Joint
             Committee on Cancer [AJCC] 8th edition) NSCLC that is unresectable and not fit for
             radical concurrent chemoradiotherapy, or metastatic / recurrent non-squamous NSCLC;

          4. Patients with EGFR mutation confirmed by tumor histology or cytology or hematology
             prior to EGFR-TKI treatmen

          5. EGFR-TKI resistance, confirmed by RECIST 1.1

          6. The investigator confirms at least one measurable lesion according to RECIST 1.1. A
             measurable lesion located in the field of previous radiation therapy or after local
             treatment may be selected as a target lesion if progression is confirmed;

          7. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

        Exclusion criteria:

          1. Squamous cell &gt; 10%. If small cell types are present, the subject is not eligible for
             inclusion.;

          2. Has previously received systemic anti-tumor treatment other than EGFR-TKI (including
             cytotoxic chemotherapy for radiotherapy, do not include other systemic treatment for
             other cured tumors);

          3. Has previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2
             drugs or any other stimulatory or inhibitory agents of T cell receptors (eg CTLA-4,
             OX-40, CD137);

          4. Has received EGFR-TKI treatment within 2 weeks;

          5. Diagnosed of immunodeficiency or has received systemic steroid therapy or any other
             form of immunosuppressive therapy within 7 days prior to the first dose of study
             drugs.

          6. History of pneumonitis requiring steroid therapy or the presence of interstitial lung
             disease within 1 year prior to the first dose of study drugs;

          7. Active central nervous system (CNS) metastasis and/or cancerous meningitis.

          8. Hemoptysis within 3 months,

          9. Full-dose oral or parenteral anticoagulant or thrombolytic agent for 10 consecutive
             days within 2 weeks. prophylactic use of anticoagulants is allowed;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>tengfei zou</last_name>
    <phone>+86 0512-69566088</phone>
    <email>tengfei.zou@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, M.D.,Ph.D</last_name>
      <phone>021-32260856</phone>
      <email>shun_lu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

